Navigation Links
A novel computational model -- how Parkinson's medications affect learning and attention
Date:1/20/2010

Newark, NJ A new brain-based computational model is helping to understand how Parkinson's disease and dopamine medicationsused to treat motor symptoms caused by the disease can affect learning and attention.

As reported in a forthcoming article in the Journal of Cognitive Neuroscience, http://www.mitpressjournals.org/doi/pdf/10.1162/jocn.2010.21420, a new computational model, developed by Drs. Ahmed Moustafa and Mark Gluck, at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark, has shown how Parkinson's disease affects attentional performance during learning.

The same model also shows that dopamine medications enhance attentional performance in Parkinson's patients in agreement with past observations. Future lab experiments with Parkinson's patients will be conducted by Moustafa and Mark Gluck to test further model predictions.

Parkinson's is a disease that mainly affects dopamine levels in a brain area known as the basal ganglia, which is important for motor control. Hence, damage to this area leads to movement disorders, including shaking and difficulty moving--key symptoms of Parkinson's disease.

Over the past two decades, it became known to neurologists and experimental neuroscientists that Parkinson's disease also affects non-motor functions, including memory, learning, and attention. Impairment in these processes affect the quality of life of the patients, thus, understanding the neural basis of motor and non-motor dysfunction in Parkinson's disease is equally important.

Dopamine is also projected to other parts of the brain, including the prefrontal cortex, an area important for higher-level thinking, decision making, and attention. Dopamine projected to the prefrontal cortex is also reduced in Parkinson's disease, as reported in many experimental studies with humans and animal models of Parkinson's disease.

According to Moustafa and Gluck, until recently, existing computational models of Parkinson's disease ignored any role played by dopamine in the prefrontal cortex. Moustafa and Gluck have designed a new computational model that shows how dopamine in the prefrontal cortex is important for attentional performance, and how dysfunction of dopamine in the prefrontal cortex can explain many of the non-motor deficits seen in Parkinson's patients.

"Computational models are increasingly being used in the neurosciences and neurology to understand how neurological disorders affect brain and behavior," said Moustafa. "This relatively new fieldknown as computational neuroscience is promising to aid in designing new pharmacological and surgical intervention tools to treat neurological and psychiatric diseases."


'/>"/>

Contact: Helen Paxton
paxton@andromeda.rutgers.edu
973-353-5262
Rutgers University
Source:Eurekalert

Related medicine news :

1. TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
2. New human reproductive hormone could lead to novel contraceptives
3. Researchers discover novel method for detecting MIRCERA
4. Novel detection method unmasks circulating breast cancer cells
5. Turning metal black more than just a novelty
6. Engineers, doctors at UCLA develop novel material that could help fight arterial disease
7. Novel Technology in Treating Chronic Sinus Infections Available at Baptist
8. Novel K-anonymity algorithm safeguards access to data
9. Tulane Cancer Center to begin novel clinical trial for late-stage prostate cancer drug
10. Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
11. Dallas Facial Plastic Surgeon Publishes Cutting-Edge Novel Approach To Facelift Technique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Mother Nature isn’t the only mom ... fruits and vegetables. , Celebrate these women with more than just a bouquet ... with these five garden-themed options. , Vibrant, Edible, Compact Plants from BrazelBerries: , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... to identify, fund and implement ideas aimed at improving care and reducing readmission ... “Part of our vision for Trinity Health is to drive innovation that transforms ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and Vancouver, WA, has announced the latest beneficiary of their ongoing community ... and their Mammography Program, which provides free mammograms and diagnostic breast care ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  It,s time for an upgrade. There are many medical recorders on the market ... the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned ... manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... BRIDGEWATER, New Jersey , May 4, 2016 /PRNewswire/ ... today its successful completion of an alternative public offering ... its wholly owned operating company, Valeritas, Inc. and a ... unregistered common stock at $5.00 per share. ... completed on May 3, 2016, Valeritas Holdings, Inc. will ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology: